Manufacturing CAR-NK against tumors: Who is the ideal supplier?  

作　　者：Feifei Guo Yi Zhang Jiuwei Cui 

机构地区：[1]The First Hospital of Jilin University,Cancer Center,Changchun 133021,China

出　　处：《Chinese Journal of Cancer Research》2024年第1期1-16,共16页中国癌症研究（英文版）

摘　　要：Chimeric antigen receptor-natural killer(CAR-NK) cells have emerged as another prominent player in the realm of tumor immunotherapy following CAR-T cells. The unique features of CAR-NK cells make it possible to compensate for deficiencies in CAR-T therapy, such as the complexity of the manufacturing process, clinical adverse events, and solid tumor challenges. To date, CAR-NK products from different allogeneic sources have exhibited remarkable anti-tumor effects on preclinical studies and have gradually been applied in clinical practice.However, each source has advantages and disadvantages. Selecting a suitable source may help maximize CAR-NK cell efficacy and increase the feasibility of clinical transformation. Therefore, this review discusses the development and challenges of CAR-NK cells from different sources to provide a reference for future exploration.

关 键 词：CAR-NK cells cord blood IPSC NK-92 cells peripheral blood 

分 类 号：R730.51[医药卫生—肿瘤]